KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.

N Engl J Med · 2025-Feb-13 · PMID 39282913

Panel Panel_B质量警告待 EXE 对齐验证

Overall Survival

Figure 2:. Progression-free Survival According to Blinded Independent Central Review and Overall Survival of Patients Enrolled in the Pancreatic NET Cohort Panel A demonstrates the results of progression-free survival (PFS), as assessed retrospectively per RECIST 1.1 criteria by blinded independent central review (BICR), for patients enrolled in the pNET cohort. For the comparison between treatment groups, two-sided stratified log-rank P-value <0.001. Panel B demonstrates the results of overall survival of patients enrolled in the pNET cohort. Panel C demonstrates the results of PFS according to stratification factors and selected clinical subgroups of patients enrolled in the pNET cohort. For the Histologic Differentiation subgroup analysis, “Moderately differentiated” and “Not specified” subgroups are not displayed in the figure due to having zero PFS events in at least one treatment arm.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.61
质量通过否
预期曲线2
实际曲线1
X 范围0 – 66
Y 范围0 – 100

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

匹配 16 行
Curve序号X (norm)Y (norm)X (real)Y (real)X (pixel)Y (pixel)
210.00811.00000.5203100.000018813
220.27070.730917.466273.0949416186
230.27190.729417.540572.9393417187
240.27300.729417.614972.9393418187
250.27420.729417.689272.9393419187
260.27530.729417.763572.9393420187
270.27650.727817.837872.7838421188
280.27760.727817.912272.7838422188
290.27880.727817.986572.7838423188
2100.28000.727818.060872.7838424188
2110.28110.727818.135172.7838425188
2120.28230.727818.209572.7838426188
2130.28340.730918.283873.0949427186
2140.28460.730918.358173.0949428186
2150.28570.730918.432473.0949429186
2160.28690.729418.506872.9393430187
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T18:10:15+00:00